ArticleJournal of medical genetics2022
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
Article in Journal of medical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06564428 (A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · 2025Guideline
- Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.British journal of cancer · 2026Article
- Priorities for breast cancer risk assessment in UK women under age 50: a survey and discrete choice experiment.British journal of cancer · 2026Article
- Moderate-risk variants in hereditary breast and ovarian cancer: seven-year experience from a specialized center.Familial cancer · 2026Article
- Article
- Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis.British journal of cancer · 2026Article
- Knowledge-Guided Explainable Recommendation Tool for Cancer Risk Prediction Models Using Retrieval-Augmented Large Language Models: Development and Validation Study.JMIR medical informatics · 2026Article
- Modeling Individual-Level Uncertainty From Missing Data in Multifactorial Breast Cancer Risk Prediction.JCO precision oncology · 2026Article
- Acceptability of breast cancer risk assessment for women aged 30-49: Views of women from six under-served groups.PloS one · 2026Article
- Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer.NPJ genomic medicine · 2025Article
- Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.British journal of cancer · 2025Article
- Primary care online training on multifactorial breast cancer risk: pre-post evaluation study.BJGP open · 2025Article
- Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.JAMA network open · 2025Observational
- Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model.JCO precision oncology · 2025Article
- Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention.JAMA oncology · 2025Article
- Economic evaluation of personalised versus conventional risk assessment for women who have undergone testing for hereditary breast and ovarian cancer genes: a modelling study.Journal of medical genetics · 2025Article
- Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE.Breast cancer research : BCR · 2025Article
- Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank.Journal of the National Cancer Institute · 2025Article
- Review
- Overlap of high-risk individuals across family history, genetic & non-genetic breast cancer risk models: Analysis of 180,398 women from European & Asian ancestries.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 6 countries.
Funding
Abstract
backgroundBOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) for breast cancer and the epithelial tubo-ovarian cancer (EOC) models included in the CanRisk tool (www.canrisk.org) provide future cancer risks based on pathogenic variants in cancer-susceptibility genes, polygenic risk scores, breast density, questionnaire-based risk factors and family history. Here, we extend the models to include the effects of pathogenic variants in recently established breast cancer and EOC susceptibility genes, up-to-date age-specific pathology distributions and continuous risk factors.
methodsBOADICEA was extended to further incorporate the associations of pathogenic variants in
results
conclusionsThese extensions will allow for better personalised risks for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.